Fig. 7From: Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s diseaseThe application of the predictive model to patients with AD, aMCI, VaD, PDD, bvFTD, and DLB. The linear regression analyses were performed in patients with AD, aMCI, VaD, PDD, bvFTD, and DLB (a). By applying model, the predicted P-tau/Aβ42 ratio in CSF was compared between AD, aMCI, and non-AD subjects (combination of controls, VaD, PDD, bvFTD, and DLB) (b). The predicted P-tau/Aβ42 ratio successfully differentiated patients with AD from non-AD (c). The predicted P-tau/Aβ42 ratio was also compared between aMCI and Non-AD (d) and AD and aMCI (e). Abbreviations: AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; VaD, vascular dementia; PDD, Parkinson disease dementia; bvFTD, behavioral variant frontotemporal dementia; DLB, dementia with Lewy body; AUC, area under the curveBack to article page